VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DNTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksDNTHInstitutional Holders

DNTH logoDianthus Therapeutics, Inc. (DNTH) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership increased this quarter (+7.92 pp), with a relatively well-distributed shareholder base.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
158.7%$5.8B total value · ▲ +7.92 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
67 / 100Bullish
Institutions & Flow271 holders+25 net flow (+58 / -33)

AI Insights & Key Takeaways

  • Positive Institutional Flow (+25)
  • Citadel Advisors Llc maintains a significant position
  • Top 10 holders control 49.8% of institutional value
  • No Insider Signal

Top Institutional Holders of DNTH

Ranked by reported Q2 2026 13F market value

Top 10 Holders
49.8%
Top 25 Holders
72.7%

Share of total reported institutional value in DNTH held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1FMR LLC8.2M$799.3M+5.6%19.640%0.03%
2BlackRock, Inc.4.1M$402.0M+29.9%9.877%0.01%
3WELLINGTON MANAGEMENT GROUP LLP3.2M$314.8M+24.4%7.736%0.05%

Quarterly Institutional Activity

Filings activity in DNTH during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers58Added To154Trimmed52Exited33
  • WESTFIELD CAPITAL MANAGEMENT CO LP$30.7M
  • Assenagon Asset Management S.A.$27.4M

DNTH Institutional Ownership by Quarter

8 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 2026271+12%158.66%+7.92 pp$5.78B+16%
Q1 2026243+46%150.74%+1.42 pp$4.99B+150%
Q4 2025166+18%149.32%+3.76 pp$1.99B+7.2%
Q3 2025141+36%145.56%14.20 pp$1.86B+156%
Q2 2025104+5.1%159.76%+3.40 pp$726M+8.0%
Q1 202599+3.1%

How DNTH Compares to Peers

Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
LKFTLakefront Biotherapeutics N.V.$2.19B49.6%79-12
YARWYarrow Bioscience Inc$145M1.2%47+2
RKTORocket One Inc.$9M7.9%22+3

DNTH — Frequently Asked Questions

Quick answers to the most common questions about buying DNTH stock.

What percentage of DNTH is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of Dianthus Therapeutics, Inc. stands at 158.7%, held across 271 reporting institutions.

Who is the largest institutional holder of DNTH?

FMR LLC is the largest reported institutional holder of DNTH, with approximately 8,199,893 shares worth $0.80B as of Q2 2026.

Is DNTH a hedge fund favorite?

Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of DNTH, including CITADEL ADVISORS LLC.

What is DNTH's Smart Money Score?

Our composite Smart Money Score for DNTH is 67 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought DNTH this quarter?

58 institutions opened new positions in DNTH during Q2 2026, while 33 fully exited. 154 added to existing positions and 52 trimmed.

4Fairmount Funds Management LLC2.5M$247.3M0.0%6.077%16.35%
5STATE STREET CORP2.4M$229.8M+68.5%5.647%0.00%
6VANGUARD CAPITAL MANAGEMENT LLC2.2M$210.5M+6.3%5.173%0.00%
7Avidity Partners Management LP2.1M$205.1M0.0%5.040%32.85%
8Octagon Capital Advisors LP1.8M$179.5M-5.4%4.411%16.14%
9TCG Crossover Management, LLC1.7M$163.4M0.0%4.016%3.93%
10FRED ALGER MANAGEMENT, LLC1.3M$127.0M+12.1%3.120%0.42%
11GEODE CAPITAL MANAGEMENT, LLC1.3M$122.7M+37.4%3.014%0.01%
12Venrock Adviser, LLC1.2M$115.0M0.0%2.826%3.49%
13UBS Group AG1.1M$111.2M+46.0%2.731%0.01%
14DEERFIELD MANAGEMENT COMPANY, L.P.1.1M$109.7M+10.3%2.695%1.14%
15CITADEL ADVISORS LLC1.0M$100.0M-37.8%2.457%0.01%
16JENNISON ASSOCIATES LLC1.0M$99.6M+110.6%2.447%0.06%
17Polar Capital Holdings Plc1.0M$99.3M-5.3%2.440%0.23%
18FRANKLIN TEMPLETON INC969K$94.5M+0.1%2.321%0.02%
19BAKER BROS. ADVISORS LP852K$83.1M0.0%2.041%0.42%
20Logos Global Management LP800K$78.0M+100.0%1.916%3.36%
21Cormorant Asset Management, LP750K$73.1M-21.1%1.796%3.75%
22ALLIANCEBERNSTEIN L.P.834K$70.0M-9.9%1.998%0.02%
23BRAIDWELL LP595K$58.0M-33.9%1.424%2.14%
24VANGUARD PORTFOLIO MANAGEMENT LLC570K$55.6M+63.2%1.365%0.00%
25AMERIPRISE FINANCIAL INC532K$51.9M+24.0%1.274%0.01%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in DNTH — a direct measure of their conviction.

EMERALD ADVISERS, LLC
$24.2M
  • TimesSquare Capital Management, LLC$16.2M
  • Eagle Health Investments LP$12.8M
  • EMERALD MUTUAL FUND ADVISERS TRUST$12.8M
  • ORBIMED ADVISORS LLC$11.2M
  • TWO SIGMA INVESTMENTS, LP$10.5M
  • FIRST TRUST ADVISORS LP$9.2M
  • MERCER GLOBAL ADVISORS INC /ADV$6.4M
  • Jones Hill Capital LP$5.6M
  • Verition Fund Management LLC$3.9M
  • 156.36%
    +9.95 pp
    $673M
    11%
    Q4 202496+5.5%146.41%+6.49 pp$755M12%
    Q3 202491—139.92%—$855M—

    Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

    How is institutional ownership of DNTH changing?

    DNTH institutional ownership rose by 7.92 percentage points quarter-over-quarter, with a net change of +28 holders.

    How concentrated is DNTH ownership among the top holders?

    The top 10 institutions account for 49.8% of all reported 13F value in DNTH, and the top 25 account for 72.7%.

    How does DNTH compare to Immunology Biotech on institutional ownership?

    Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.

    Where does this DNTH institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    DNTHDianthus Therapeutics, Inc.
    $83.98$3.5B
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership